CBPO  China Biologic Products Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

2.45B

Vuru Grade

67.23/100

Current Price

$98.59
-0.35 (-0.35%)

Growth Price

$42.52
Overvalued by 56.88%

Stability Price

$19.79
Overvalued by 79.92%

Company Metrics

  • 36.38 P/E
  • 10.09 P/S
  • 11.57 P/B
  • 2.71 EPS
  • 31.13% Cash ROIC
  • 0.67 Cash Ratio
  • 0 / 0% Dividend
  • 108,873.00 Avg. Vol.
  • 24.85M Shares
  • 2.45B Market Cap.

Company Description

China Biologic Products, Inc., a biopharmaceutical company, engages in the research, development, production, and manufacture of plasma-based pharmaceutical products in the People's Republic of China. It offers Human Albumin for the treatment of shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

New Lifetime High Reached By China Biologic Products (CBPO)
TheStreet.com - Mar 27, 2015
China Biologic Products, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China.
Today's Insights: China Biologic Products, Inc. (CBPO), Boise Cascade ... - WallStreet Scope
China Biologic Products Q4 2014 Earnings: Primed For A Sell-Off? (CBPO)
Seeking Alpha (registration) - Feb 23, 2015
Before Q2 earnings on August 5, I wrote a bullish article on China Biologic Products (NASDAQ:CBPO), with a thesis stating that the company's plasma-based products should benefit from increasing market demand in China for Q2. I argued that the company's ...
Trade-Ideas: China Biologic Products (CBPO) Is Today's New Lifetime High Stock
TheStreet.com - Mar 20, 2015
China Biologic Products, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China.
China Biologic Products Earnings Preview (CBPO)
Seeking Alpha (registration) - Aug 5, 2014
China Biologic Products (NASDAQ: CBPO), a biopharmaceutical company focused on developing plasma-based products, has been subjected to a roller coaster ride over the last several months. Back in mid June, shares fell more than 11% after the ...
Stock in Focus : China Biologic Products, Inc. (NASDAQ:CBPO)
Markets Wired - Feb 18, 2015
China Biologic Products, Inc. (NASDAQ:CBPO) (TREND ANALYSIS) shares were traded with more than 50% increase in usual volume.
Earnings Watchlist - China Biologic Products, Inc. (NASDAQ:CBPO)
The Markets Daily - Apr 20, 2015
As China Biologic Products, Inc. (NASDAQ:CBPO) prepares to next report their earnings on or around 2015-05-05, investors will be keeping a close eye on the reported earnings per share figure and how it compares to the Wall Street analyst consensus ...
Moving Stocks: Solazyme, Inc. (NASDAQ:SZYM), China Biologic Products, Inc ... - Stock Transcript
Mid-Day Changers: China Biologic Products, Inc. (CBPO), Lifetime Brands, Inc ... - WallStreet Scope
China Biologic Products, Inc. (CBPO) Jumps: Stock Surges 10.8%
Zacks.com - Jul 9, 2014
China Biologic Products, Inc. (CBPO - Snapshot Report) was a big mover last session, as the company saw its shares rise nearly 11% on the day.
China Biologic Products, Inc. (CBPO) Rises: Stock Jumps 7.4%
Zacks.com - Aug 27, 2014
China Biologic Products, Inc. (CBPO - Snapshot Report) was a big mover last session, as the company saw its shares rise more than 7% on the day.
Update: China Biologic Products Adopts Stockholder Plan To Avoid Hostile ...
Seeking Alpha - Jan 9, 2015
Before Q2 earnings on August 5, I wrote a bullish article on China Biologic Products (NASDAQ:CBPO), with a thesis stating that the company's plasma-based products should benefit from increasing market demand in China for Q2. I argued that the company's ...
Update: China Biologic Products Q3 Earnings Beat (CBPO)
Seeking Alpha (registration) - Nov 6, 2014
Before Q2 earnings on August 5, I wrote a bullish article on China Biologic Products (NASDAQ:CBPO), with a thesis stating that the company's plasma-based products should benefit from increasing market demand in China for Q2. I argued that the company's ...